Teva
HERZUMA
Manufacturer:
Teva
Name:
HERZUMA
HCPCS Code Descriptor:
Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Category:
Q Code
HCPCS:
Q5113
NDC(s):
63459-0305-47, 63459-0303-43
Primary Type:
Oncology Biosimilar
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
HERZUMA is an Oncology Biosimilar drug manufactured by Teva and administered via the Intravenous route of administration. The Q Code: Q5113 is aligned to the drug HERZUMA.
Herzuma (trastuzumab) is used to treat specific types of breast and stomach cancers by targeting the HER2 protein in cancer cells. Herzuma can be used in combination with other cancer medications. This medication is manufactured by Cephalon and is biosimilar to the medication Herceptin (J9356). Herzuma has been aligned to the Q Code Q5113 since July 2019. Patient assistance programs for this medication can be found through Truxima.